Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Hisamitsu Pharmaceutical Co ( (JP:4530) ).
TAIYO KOSAN CO., INC. has launched a tender offer to acquire common shares, share acquisition rights, and depository receipts of Hisamitsu Pharmaceutical Co., Inc., signaling an attempt by the president-controlled entity to significantly increase its ownership in the listed drug maker. The move, made under Japan’s Financial Instruments and Exchange Act, could tighten control of Hisamitsu by its current leadership, potentially altering the company’s governance structure and ownership balance while reinforcing founder-related influence over the publicly traded business.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen4677.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japan-based pharmaceutical company best known for its topical pain relief and related therapeutic products, and its shares are listed on the Prime Market of the Tokyo Stock Exchange, the Premier Market of the Nagoya Stock Exchange, and the Main Market of the Fukuoka Stock Exchange. TAIYO KOSAN CO., INC., founded in 1987 and focused on asset management services, is an investment vehicle wholly owned by Hisamitsu’s president, Kazuhide Nakatomi, and already holds a minority stake in the drug maker.
Average Trading Volume: 183,723
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen328.3B
See more data about 4530 stock on TipRanks’ Stock Analysis page.